Carta ao editor

Neto, Vicente Amato; Lopes, Marta Heloísa

doi:10.1590/s0037-86822001000200012

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitantly, the patient had glucose-6-phosphate dehydrogenase deficiency (G6PD), and the coincidence with hemolytic crisis, and also an interaction with BNZ, cannot be excluded. A similar situation was described in a summary presented at a scientific event in which the authors reported an individual with Cd who had direct (1.6 mg/dl) and indirect (4.6 mg/dl) bilirubin elevation with regular AST and ALT levels, besides anemia, after 28 days of BNZ use [ 28 ]. Studies with large numbers of patients informing hepatic AE report no jaundice, no hyperbilirubinemia and no hemolysis dependent on this drug.…”

Section: Discussionsupporting

confidence: 58%

Hepatic changes by benznidazole in a specific treatment for Chagas disease

et al. 2018

View full text Add to dashboard Cite

Chagas disease (Cd) is the third most common parasitic disease that causes damage to human health. Even a century after its description by Carlos Chagas and advances in its control, it remains a neglected disease. To eradicate the parasite or reduce the parasitic load, specific treatment for Trypanosoma cruzi (T. cruzi) is advisable; benznidazole (BNZ) is the drug that is currently prescribed. The purpose of this study is to report the adverse events (AE) due to the use of BNZ as a specific treatment for Cd, with a particular focus on hepatic changes. This was an observational, cross-sectional cohort study that included patients who were treated with BNZ. The medical records of patients who joined the Grupo de Estudo em doença de Chagas [Chagas Disease Study Group]/UNICAMP/Brazil and were treated with BNZ were reviewed for epidemiological, clinical, laboratory and AE parameters for the drug. The 204 patients who were assessed had an average age of 40.6 years ± 13.5 years, and 104 of them were women (50.98%). Fourteen (6.86%) individuals were in the acute phase of Cd, and 190 (93.13%) were in its chronic phase. AEs occurred in 85 patients (41.66%), 35 (41.17%) of whom had AEs related to the liver, characterized by an elevation of AST liver enzymes, ALT, alkaline phosphatase and gamma-glutamyltransferase (γGT). Other AEs that were observed included the following: 48 cases of cutaneous changes (56.47%), 8 cases of epigastric pain (9.41%), 7 cases of blood alteration (8.23%), and 3 cases of peripheral neuropathy (3.52%). Treatment was interrupted in 32 patients (37.64%) due to AD. Adverse events related to the liver secondary to the use of BNZ for Cd-specific treatment were frequent in this study and were characterized by an elevation of liver enzymes. Therefore, it is suggested that these enzymes be monitored during treatment with benznidazole.

show abstract

Section: Discussionsupporting

confidence: 58%